Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response

Anna Sosnowska; Malgorzata Czystowska-Kuzmicz; Jakub Golab

doi:10.1080/2162402X.2019.1655370

Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response

Oncoimmunology. 2019 Aug 20;8(11):e1655370. doi: 10.1080/2162402X.2019.1655370. eCollection 2019.

Authors

Anna Sosnowska^{1

2}, Malgorzata Czystowska-Kuzmicz¹, Jakub Golab^{1

3}

Affiliations

¹ Department of Immunology, Medical University of Warsaw, Warsaw, Poland.
² Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland.
³ Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland.

Abstract

Expression of arginase-1 (ARG1) is an immunosuppressive feature of tumor microenvironment that leads to depletion of ʟ-arginine, a nutrient required for T-cells expansion. Ovarian carcinoma cells release extracellular vesicles carrying enzymatically active ARG1, that contributes to local and systemic immune suppression, which can be restored by ARG inhibitor.

Keywords: Arginase; T-cells response; extracellular vesicles; immunotherapy; ovarian carcinoma.